Skip to main content
. 1998 Oct;42(10):2590–2594. doi: 10.1128/aac.42.10.2590

TABLE 1.

Origin and properties of the S. aureus strains

Strain Date of isolation (mo/yr) Origin Patient’s therapy Resistance phenotypea Rifampin MIC (μg/ml)
BM4626 4/1992 Bone Rifampin plus pefloxacin Tc 0.008
BM4627 4/1992 Pef Rif Tc 128–256
BM4364 2/1996 Bone Vancomycin, followed by rifampin plus pristinamycin Emc Fos Fus Km Met Pc Pef Tm 0.008
BM4364-R 3/1996 Emc Fos Fus Km Met Pc Pef Rif Tm 256
BM4365 6/1996 Blood Rifampin Pc 0.008
BM4365-R 10/1996 Pc Rif 256
BM4366 1/1997 Skin Rifampin Pc Emc 0.008
BM4366-R 1/1997 Pc Emc Rif 128–256
BM4367 3/1997 Urine Rifampin plus vancomycin Emc Fos Km Met Pc Pef Tm 0.016
BM4367-R 4/1997 Urine and pulmonary tree Emc Fos Km Met Pc Pef Rif Tm 4
BM4368 3/1997 Urine Rifampin plus vancomycin Pc Tc 0.016
BM4368-R1 3/1997 Pulmonary tree Rifampin plus vancomycin Pc Rif Tc 128
BM4368-R2 4/1997 Pulmonary tree Pc Rif Tc 4
a

Emc, constitutive resistance to macrolide, lincosamide, and streptogramin β-type antibiotics; Fos, resistance to fosfomycin; Fus, resistance to fusidic acid; Km, resistance to kanamycin; Met, resistance to methicillin; Pc, resistance to penicillin G; Pef, resistance to pefloxacin; Rif, resistance to rifampin; Tm, resistance to tobramycin.